ClinicalTrials.gg
Sign In
Not yet recruitingNCT07916142Updated Nov 4, 2026

Effect of Antenatal Dexamethasone on Postnatal Adrenal Hormones in Preterm Neonates

An observational study in Preterm Birth Infants, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 0 Days to 7 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Sohag University · Observational

Updated Nov 4, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
0 Days to 7 Days
Sex
All
01

Study summary

This study is designed to evaluate the effect of antenatal dexamethasone administration on postnatal adrenal hormone levels in preterm neonates. The research aims to assess how prenatal exposure to corticosteroids impacts the adrenal function of newborn infants during the postnatal period.

02

Conditions studied

  • Preterm Birth Infants

Keywords

  • Dexamethasone
  • Adrenal Hormones
03

In context

Lead sponsor

Sohag University is the lead sponsor of 1,225 studies on the registry; 632 are open to participants now.

Browse Sohag University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 7 Days
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Preterm neonates born at Sohag University Hospital who meet the inclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Preterm neonates admitted to the neonatal intensive care unit (NICU).
  • Gestational age less than 37 weeks.

Exclusion criteria

Exclusion Criteria:

  • - Major congenital anomalies.
  • Congenital adrenal hyperplasia or endocrine disorders.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • Preterm neonates exposed to antenatal dexamethasone

    Preterm infants whose mothers received antenatal dexamethasone.

  • Control Group

    Preterm infants whose mothers did not receive antenatal dexamethasone.\& full term

06

What researchers measure

Primary outcomes

  1. Postnatal Adrenal Hormone Levels

    Measurement of serum cortisol and other adrenal hormone levels in preterm neonates during the postnatal period.

    Time frame: During the first week of life (e.g., at 24, 48, and 72 hours postnatally)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 4, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Nov 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07916142
Lead sponsor
Sohag University
Responsible party
Nancy Maher Sobhy (Pediatric resident , sohag university, Sohag University) — Principal investigator
First posted
Nov 4, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Nancy M Atia, M.B.B.Ch, M.Sc. candidate
Contact
nancymaher714@gmail.com
+201212295030
Atia
principal investigator · Sohag University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Sohag University →

Start the discussion